Video Series
Episode 1: The vision
Traditional cell therapy manufacturing is hitting a logistical plateau that restricts patient access worldwide. Discover how the concept of the body as a bioreactor could shift the paradigm from external engineering to internal healing.
This video explores the visionary shift from ex vivo to in vivo therapeutics, where we provide the body with molecular instructions to produce its own medicine. It is designed for biotech professionals and healthcare advocates looking to understand how this dual-modality approach can achieve true global therapeutic equity.
In this episode, you will learn:
- The “in vivo advantage”: Why tapping into the body’s built-in processes would be a game-changer for patient experience.
- Overcoming logistics: How moving away from centralized manufacturing would make it easier to produce and deliver advanced genomic medicines to more patients.
- Global scalability: The potential to reach under-resourced regions, such as sub-Saharan Africa, where infrastructure is a barrier.
- The design space: Why this would be an expansion, not a replacement, of the current cell therapy gold standard.
By the end, you will understand how leveraging the body’s endogenous mechanisms can make advanced genomic medicine more sustainable and avoid the prohibitive costs of traditional external reactors.
Read more about in vivo manufacturing and thevision behind the body as a bioreactor